CALGARY, ALBERTA -- (MARKET WIRE) -- March 07, 2007 -- Resverlogix Corp. (“Resverlogix”) (TSX: RVX) is pleased to announce today favorable results from 28-day toxicology studies conducted on its lead drug compound RVX-208. With the completion of this critical component of the drug development program for RVX-208, the focus will shift toward completion of an Investigational New Drug (IND) application to support clinical development.
